Transaction #9028 · Form 4 · 0001834681-25-000005
Niagen Bioscience, Inc. · Purchase · Common Stock
Niagen Bioscience, Inc. · Transacted November 14, 2025 · Filed November 17, 2025
What does this filing report?
An SEC Form 4 filing for Niagen Bioscience, Inc. records a purchase involving Common Stock on November 14, 2025. The reported quantity was 2,220.443. The filing date is November 17, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Niagen Bioscience, Inc.
- Company CIK
- 0001386570
- Security type
- Non-derivative
- Acquisition type
- Purchase · Code P
- Quantity acquired
- 2,220.443
- Reported price
- 6.85
- Reference value
- 15,210.03455
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 2,220.443
- Ownership description
- The reported securities are held by the reporting person's spouse.
- SEC acceptance time
- Nov 17, 2025, 8:23 AM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Pamir Ozan ↗
Chief Financial Officer
CIK 0001834681
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- The weighted average purchase price for the transaction reported was $6.81, and the range of prices were between $6.7975 and $6.82, inclusive. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range above will be provided.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.